跳至主要内容
临床试验/ACTRN12624001158550
ACTRN12624001158550尚未招募Unknown

Ghrelin and sympathetic nerve activity in Pacific People (SNAPP)

University of Auckland0 个研究点目标入组 120 人开始时间: 2024年9月24日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
入组人数
120
主要终点
Plasma levels of ghrelin in healthy Pacific Island (PI), compared to healthy New Zealanders (NZ) Europeans.[Plasma ghrelin concentration will be assessed by blood sample.<br> Plasma levels of ghrelin will be assessed once at the experimental visit in healthy PI and healthy NZ Europeans participants.<br>];Muscle sympathetic nerve activity (MSNA) in healthy Pacific Island (PI), compared to healthy New Zealanders (NZ) Europeans[MSNA will be assessed by microneurography. MSNA in healthy PI and NZ Europeans participants will be assessed at four timepoints during the experimental visit: at rest, during slow deep breathing, during Valsalva manoeuvre and during hyperoxia.]

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 No limit(—)
性别
All

入选标准

  • All cohorts: Men and women aged 18 years or older; Cohort 1: Healthy Pacific Island (both biological parents of Pacific Island origin) participants Healthy NZ European (both biological parents of New Zealand origin) participants Healthy Pacific Island (both biological parents of Pacific Island origin) living in NZ or Samoa; Cohort 2: Healthy NZ European participants; Cohort 3: T2D Pacific Island (both biological parents of Pacific Island origin) participants T2D NZ European (both biological parents of New Zealand origin) participants •Pacific Island (both biological parents of Pacific Island origin) and non-Pacific (NZ European) participants •Healthy participants •Type 2 diabetics

排除标准

  • Severe cardiac disease (e.g., coronary artery disease, heart failure)•Significant arrhythmias (e.g., atrial fibrillation, previous VT / significant ventricular ectopy)•Severe respiratory disease (e.g., chronic obstructive pulmonary disease)•Significant renal or liver disease•Significant neurological disease including diabetic neuropathy•Significant obesity (i.e., not having a body fat% >30% for men and >42% for women)•Current active treatment for cancer•Inflammatory disease•Current infection or pyrexial illness•Uncontrolled thyroid disorders•Recent (< 3 months) ischemic stroke•Current pregnancy•Inability to fully or appropriately provide consent (e.g., language issue, reading capability)•Underlying medical conditions, which in the opinion of the Investigator place the participant at unacceptably high risk for participating in the study

结局指标

主要结局

Plasma levels of ghrelin in healthy Pacific Island (PI), compared to healthy New Zealanders (NZ) Europeans.[Plasma ghrelin concentration will be assessed by blood sample.<br> Plasma levels of ghrelin will be assessed once at the experimental visit in healthy PI and healthy NZ Europeans participants.<br>];Muscle sympathetic nerve activity (MSNA) in healthy Pacific Island (PI), compared to healthy New Zealanders (NZ) Europeans[MSNA will be assessed by microneurography. MSNA in healthy PI and NZ Europeans participants will be assessed at four timepoints during the experimental visit: at rest, during slow deep breathing, during Valsalva manoeuvre and during hyperoxia.]

次要结局

  • The levels of ghrelin in type 2-diabetic (T2D) PI populations compared to T2D NZ European population.[Plasma ghrelin concentration will be assessed by blood sample. Plasma levels of ghrelin will be assessed once at the experimental visit in T2D PI and T2D NZ Europeans participants.];MSNA in T2D PI compared to T2D NZ European. [Muscle sympathetic nerve activity will be assessed by microneurography. MSNA in T2D PI and NZ Europeans participants will be assessed at four timepoints during the experimental visit: at rest, during slow deep breathing, during Valsalva manoeuvre and during hyperoxia.]

研究者

相似试验